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Features and Clinical Effectiveness 
of the Regenerative Injection 
Treatments: Prolotherapy 




Pain is a symptom caused by a disease process and/or tissue injury. With the 
prolongation of life expectancy in humans, the incidence of degenerative joint 
diseases and as a result pain has increased. Unfortunately, a method of treatment 
that stops or reverses progression by affecting the pathogenesis in these diseases 
has not been developed. Physical therapeutics such as medicine and physical 
rehabilitation often are prescribed for patients suffering with pain. Recently, in 
addition to these routine therapies used in pain treatment, many regenerative 
injection-based therapies, including prolotherapy (PrT) or platelet-rich plasma 
(PRP) have been widely used. PrT is using for damaged or degenerated connec-
tive tissue healing, such as ligaments, tendons, and cartilage. The combination of 
local inflammatory effect, stimulation of local growth factor release, and down 
regulation of neuropathic inflammation can be defined as the mechanism. As 
a result of these, joint instability and ligament laxity reduce and pain decrease. 
PRP is the cellular component of the plasma. Although PRP is used for the same 
reasons as PrT, it can be used in acute cases unlike PrT. This chapter is intended 
to understand the use of regenerative injection therapies (PrT and PRP) better in 
the treatment of pain.
Keywords: regenerative injection treatments, prolotherapy, platelet-rich plasma, 
musculoskeletal pain
1. Introduction
New developments are taking place every day in every field of medicine. Disease 
prevention, early diagnosis, and the definite treatment method call has become 
the target of scientists. With the prolongation of life expectancy in humans, 
the incidence of degenerative joint diseases and as a result pain has increased. 
Unfortunately, a method of treatment that stops or reverses progression by affect-
ing the pathogenesis in these diseases has not been developed.
Pain is a symptom caused by a disease process and/or tissue injury. Physical 
therapeutics, such as medicine and physical rehabilitation, often are prescribed for 
From Conventional to Innovative Approaches for Pain Treatment
2
patients suffering with pain [1]. Recently, in addition to these routine therapies used 
in pain treatment, many regenerative injection based-therapies, including prolo-
therapy (PrT) or platelet-rich plasma (PRP) have been widely used. The evidence 
for these treatments has arisen from the basic sciences and has been transformed 
into clinical research through controlled researches [2].
2. Regenerative injection treatments
2.1 Prolotherapy
PrT is derived from the words “proliferation” and “therapy” in Latin [3]. In the 
1930s, it was introduced in the USA first, but the word “Prolotherapy” was first 
used by George Hackett in 1950. Dr. Hemwall’s studies reported that 82% of the 
patients provided pain remission [4]. George Hackett formed the injection protocols 
for PrT in the 1950s depending on his clinical experience [4, 5]. Death of a case has 
been reported due to an allergic reaction due to phenol injection during PrT in 1959. 
After this negativity, this method has been removed to history [6].
PrT is an increasingly popular regenerative injection-based therapy and using 
for damaged or degenerated connective tissue healing, such as ligaments, tendons, 
and cartilage [7–10]. Following injury, chronic musculoskeletal pain develops if 
connective tissue repair is insufficient [4, 5]. Chronic musculoskeletal pain and 
disability often result from degeneration associated with these structures. PrT 
treatment can help us to correct this degeneration at the tissue level [4, 9]. We can 
correct this degeneration at the tissue level with the help of PrT. Pain reduction and 
regeneration mechanism are not clearly understood yet [7, 8]. However, the combi-
nation of local inflammatory effect, stimulation of local growth factor release, and 
down regulation of neuropathic inflammation can be defined as the mechanism  
[8, 11]. As a result of these, both joint instabilities with ligament laxity may reduce 
and also pain may reduce [12].
The proliferant solutions are used for injection into tender ligamentous and 
tendinous attachments and adjacent joint spaces. Irritants, osmotics, and che-
motactics are proliferants commonly used in PrT. Irritants are phenol, guaiacol, 
and tannic acid. These damage cells. Particulates, that is, pumice flour, are also 
irritants but make cellular trauma and attract macrophages directly. Sodium 
morrhuate is a chemotactic and attract inflammatory cells. Glucose, glycerin, and 
zinc sulphate are the osmotic proliferants and cause osmotic shock to cells [12]. 
The most common injectant used in the randomized controlled trials (RCTs) is 
hypertonic dextrose [7, 11, 13]. Proliferant solutions may cause osmotic rupture of 
cells in the area in which they are applied and may direct to growth factor increase 
in various cells of human. Also, a hypertonic environment may lead to the release 
of DNA-encoding growth factors [11, 14]. Furthermore, various proliferant 
solutions cause fibroblast stimulation. Growth factors activate and also release 
the fibroblasts. The active fibroblasts secrete new collagen fibrils. Collagen fibrils 
are essential for the repair of damaged ligament and tendons and support healing 
[4, 10]. PrT tighten and strengthen the ligaments, tendons, and joint stabilizing 
structures. So, PrT could improve the stability of the joints [4, 10, 12, 15].  
Increased joint stabilization could be associated with tissue healing process by 
increasing local blood flow and the excitability of mechanoreceptors and also by 
decreasing the excitability of pain receptors [4].
Instead of phenol, hypertonic dextrose solution can be done safely for PrT 
nowadays. The risk of side effects and complications is very low. As a result of this, 
hypertonic dextrose solutions with different concentrations (10–30%) have been 
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commonly used in studies and books to date for PrT treatments. In these studies, 
greater than 10% of dextrose solutions proposed to use inflammatory response and 
proliferation. An animal study is designed for determining the optimal concentra-
tions of dextrose solutions. This claimed that under the concentration of 10% 
only induce cell proliferation; however, do not have any effectivity on inflamma-
tion histology [16]. However, 5% dextrose solution increased gene expression in 
angiogenetic factors (platelet-derived growth factor (PDGF)-A and B, insulin-like 
growth factor-I, and vascular endothelial growth factor-A) and in apoptotic factors 
(caspase-3 and -8) in adult fibroblast culture [17]. High concentrations of glucose 
stimulate the PDGF activation. PDGF has two effects; first, it induces TGF-beta 
gene expression in mesangial cells, and second, it stimulates DNA synthesis [18]. 
Above the glucose concentrations of 10% make stimulus for the connective tissue 
growth factor and other genes expression in mesangial cells [19]. Cartilage volume 
stability improved by PrT injections, and this can be evaluated by magnetic reso-
nance imaging [16].
Excessive pain and fatigue due to inflammatory reaction can occur after the PrT 
injections. According to this rarely, treatment can be abandoned. To reduce the 
pain, hypertonic dextrose commonly combined with lidocaine, sensorcaine, and 
xylocaine as local anesthetics [20]. The local anesthetics delay and disrupt wound 
healing by inhibiting collagen synthesis in fibroblast tissue [21]. However, this 
condition disrupts the outcome of the treatment.
2.1.1 Classification
PrT can be classified as enthesofascial, myofascial, and neurofascial according to 
injection location.
2.1.1.1 Enthesofascial/intra-articular PrT
Enthesofascial/intra-articular PrT is the classic and traditional method of 
PrT. The injection location is on to the bony cortex/enthesis where the ligaments 
attach to or into joints.
2.1.1.2 Myofascial PrT
Myofascial PrT is the other type of PrT. In this type, injection location is soft 
tissue of the bony cortex and below the subcutaneous fascia. This is used for degen-
eration of muscle and tendon, tears of muscle, defects of fascia. It prevents function 
of muscle, or fascia surrounded by neovessels or neonerves.
2.1.1.3 The neurofascial PrT
The neurofascial PrT is another type for PrT. Injection location is near to the 
peripheral sensory nerves and particularly their fascial penetrations. So this is 
performed to subcutaneous tissue. The goal of PrT is repairment or functional 
restoration of soft tissue, and neurofascial PrT produces the restoration of full 
function in small nerves. The reparative proteins and their correlation with nerve 
repairment are less well known. Nerves and ligament and tendon are covering with 
mainly collagen-based structure (i.e., perineurium). Nerves must take place in 
repair of soft tissue faults and that rather probably are planned to behave a similar 
order of growth factors. According to these reasons, dextrose is potentially thera-
peutic to small nerves [3]. However, this classification of neurofacial PrT is not 
widely accepted.
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2.1.2 Indications and contraindications of PrT
Indications of PrT are chronic musculoskeletal disorders such as chronic low 
back pain, osteoarthritis, epicondylitis, and rotator cuff lesions.
Contraindications of PrT are hereditary or acquired bleeding tendency, osteo-
myelitis, systemic infection, chronic infection history or active infection in the 
treatment region, rheumatic or other systemic inflammatory disease, oncological 
diseases, having been injected local corticosteroid within 12 weeks and allergy to 
the solution that is using for PrT.
2.1.3 Disorders for PrT
2.1.3.1 Chronic low back pain
Chronic low back pain is a common disease in the population. It causes 
temporary or permanent disability [12]. The results of the studies on this subject 
contain contradictions. Intra-articular PrT injection is significantly superior to 
corticosteroid injection in sacroiliac joint pain [22]. A RCT of sclerosing injec-
tions reported that PrT has similar result as saline plus lignocaine in chronic low 
back pain [23]. Injections performed once a week for 3 weeks unlike to normal 
use. Another RCT for nonspecific chronic low back pain compared PrT injec-
tions, saline injections, and exercises. All ligament injections caused meaningful 
decreases in pain and disability along the follow-up. Results are similar for PrT 
and saline or for exercises and daily life [24]. When integrated to spinal manipu-
lation, exercise, and other interventions, PrT may have better impact on chronic 
low back pain and disability [12]. Also vitamin B12 usage increases the effective-
ness of the treatment [25].
2.1.3.2 Osteoarthritis
Knee osteoarthritis is an important disease with increasing rate of pain, func-
tional disability, and stiffness. A systematic review and meta-analysis compare 
the effect of dextrose PrT against control injections and exercise in the treatment 
of osteoarthritis. Dextrose PrT is superior to exercise, local anesthetics, and 
corticosteroids in 6 month follow-up [26]. Similar to this, a 3-arm, blinded, RCT 
compared dextrose PrT, saline, and at-home exercise, and PrT is better clini-
cal enhance of pain, function, and stiffness than saline injections and at-home 
exercises [27]. There are more studies showing the success of PrT in knee osteoar-
thritis. Injection locations are different according to researchers; a combination of 
extra and intra-articular injection [28, 29], and only intra-articular [30, 31].  
Combination of injections is thought to be an important treatment in young 
people with connective tissue disorders and also in elderly patients with severe 
knee osteoarthritis alternative to knee prosthesis. In these studies, it is reported 
that it not only reduced the pain but also corrected knee mechanical instability 
and cartilage damage.
Corticosteroid injections are an important treatment modality in symptomatic 
hand osteoarthritis [32]. The short-term effectiveness is well but the long-term 
effect is temporary. In carpometacarpal joint osteoarthritis, corticosteroid injection 
is superior to PrT at 1 month follow-up. Symptoms repeated with corticosteroid 
injection at the end of the sixth month, but improvement continued with PrT in the 
long-term and recurrence was less. PrT had better results in long term than cortico-
steroid injections [33].
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2.1.3.3 Epicondylitis
Although PrT is a promising method for the treatment of epicondylitis, there 
are contradictions in a limited number of studies. In a randomized double-blind 
study PrT and placebo injections in patients with lateral epicondylitis compared 
PrT and placebo injections in patients with lateral epicondylitis. PrT was found to 
be significantly successful in pain and function [13]. A three-arm RCT reported PrT 
with dextrose and PrT with dextrose and sodium morrhuate were similar successful 
results for pain and function than wait and see group [7]. Subsequently, a double 
blinded RCT compared PrT and the corticosteroid injections, and no difference was 
found between groups in the same indication.
2.1.3.4 Rotator cuff injuries
PrT injection to the shoulder region was first reported by Lee et al., and suc-
cessful results have shown in patients with resistant to conservative treatment [34]. 
Similar results were obtained in RCT’s [14, 35].
2.1.4 Adverse events
Adverse events change according to the localization of injections. Pain and 
stiffness may increase temporary, and these are the most common events. Also 
post-injection headache, postmenopausal spotting, pain with neurological features, 
nausea, and diarrhea may occur, but transiently [12].
2.2 Platelet-rich plasma
PRP is the cellular component of the plasma. It has a higher platelet concentration 
than whole blood [36]. Platelets are obtained by fragmentation of precursor megakary-
ocytes [37]. Activated platelets release clotting and growth factors in the α-granules. 
The main growth factors secreted by α-granules of platelets and effective in wound 
healing are known as PDGF, IGF-1, VEGF, TGF-β, and b-FGF [38]. Other factors such 
as serotonin, adenosine, dopamine, calcium, histamine, ADP, ATP, and catecholamine 
in the dens granules of platelets also play a role in tissue regeneration [39].
Growth factors assure the release of other growth factors, enhancing healing 
process in chronic injuries and quickening repair in acute lesions [38–40]. It was 
first used to accelerate the wound healing of cutaneous ulcers in the 1980s [41]. The 
potential of regeneration and curative effect of PRP in oral implantology has been 
demonstrated [42]. The usage of PRP has spread to other clinics [43].
Cellular components of plasma consist of 93% erythrocytes, 6% platelet, and 1% 
leukocytes. PRP contains platelets 3–5 times higher than whole blood. Depending 
on this, it contains growth factors in hyperphysiological rate [36].
There is no accepted clear platelet concentration value for PRP. However, there 
are studies that report the healing effect when the number of platelets up to 150,000/
μl, and 350,000/μl in whole blood is above 1,000,000/μl in 5 ml plasma [42].
PRP is provided by centrifugation of autologous anticoagulant whole blood. Prior 
to centrifugation, citrate is added to whole blood for bounding ionized calcium and 
coagulation is prevented. After centrifugation, whole blood is divided into three layers 
according to gravity. The top layer consists of plasma, the middle layer called as “buffy 
coat” consists of platelets and leukocytes, and the lowest layer consists of erythrocytes 
[43]. A second centrifuge is applied to the buffy coat and plasma section, indicating 
that PRP and platelet poor plasma may lead to further separation [44, 45].
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According to preparation technique and the resulting product ingredients, PRP 
is classified as: pure-PRP (P-PRP), leukocyte and leucocyte and PRP (L-PRP), 
and pure platelet-rich fibrin (P-PRF), leucocyte and platelet-rich fibrin (L-PRF). 
Nowadays, leukocytes can increase local inflammation, and leucocyte-poor content 
is shown to be superior to rich content. Centrifugation and activation methods are 
two important determinants of PRP quality and growth factor release. To date, 
there is no worldwide accepted PRP preparation protocol [45].
2.2.1 Indications and contraindications of PRP
Indications of PRP can be summarized as the acute/chronic musculoskeletal, 
cartilage and bone diseases such as chronic tendinopathies and enthesitis, acute/
chronic ligament injuries, acute/chronic muscle tears and strains, osteoarthritis, 
osteochondritis dissecans, arthroplasty operations, meniscus injuries, delayed 
fracture healing, nonunions, intervertebral disc injuries.
PRP’s being an autologous graft minimizes the risk of allergic reaction and infec-
tious disease. The side effects are pain formation due to local inflammatory response at 
the injection site, scar formation, and calcifications as infection and further possibili-
ties at the rate of risk at all injections. Patient selection should be performed carefully 
as there is a risk of serious allergic reaction to bowel thrombin. The contraindications 
of PRP are the presence of tumors and metastatic disease, active infection, thrombo-
cytopenia, anemia, pregnancy and lactation, and bowel thrombin allergy [46].
Acetaminophen and narcotic analgesics can be administered against pain, while 
nonsteroidal anti-inflammatory drugs are often banned for 2–4 weeks. It is thought 
that nonsteroidal anti-inflammatory drugs can inhibit the prostaglandin pathway 
and the beneficial effects of growth factors. Furthermore, in patients who received 
systemic steroids or immunosuppressive drugs, steroid injections were used instead 
of lesions in the last 6 weeks, and PRP injections were not preferred for NSAIDs in 
the last 7–10 days [36].
2.2.2 Disorders for PRP
2.2.2.1 Rotator cuff injuries
The recovery process in massive chronic rotator cuff tears often results with 
failure. PRP injection is not more effective than saline [47]. During the arthroscopic 
repair of full-thickness rotator cuff tears, PRP induces reduction in the pain level at 
the early postoperative period, a significant increase in shoulder function tests, and 
shoulder external rotation muscle strength in the short term; but there is no sig-
nificant difference in pain, function, and MRI results in the long-term [48]. While 
PRP usage did not create a difference in arthroscopic repair of full-thickness rotator 
cuff tears, PRP was better for improvement in the arthroscopic repair of small and 
medium rotator cuff tears [49].
2.2.2.2 Lateral epicondylitis
The common feature of the lateral epicondylitis studies is the standardization of 
patient selection. PRP treatment is performed by the patients with chronic lateral 
epicondylitis who did not benefit from conservative treatment. Therefore, unlike to 
other disorders, standardization of the patient selection seems to be provided in the 
lateral epicondylitis.
PRP is superior to steroid injections for reducing pain and improving function 
[50–52]. Steroid injections have better results in the first weeks, deterioration occurs 
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especially after 26 weeks [50], and at the end of the second year, patients return to 
the baseline level [51]. PRP has a progressive improvement effect [50, 51], and this 
effect continues in the long term [51].
In two studies conducted by the same author applying the same diagnosis and 
treatment, the total number of patients can be considered as 350. PRP by using the 
peppering technique is applied to extensor carpi radialis brevis tendon and vicinity. 
Success of PRP was found more than 80% after 6 months of treatment [53].
Repeated injections are not superior to single dose administration in the treat-
ment of chronic lateral epicondylitis [54].
2.2.2.3 Patellar and Achilles tendinopathy
PRP provides healing in pain and function even in patients with resistant patellar 
tendinopathy. Unlike the other injuries, 5 ml of PRP is injected into the tendon three 
times with an interval of 15 days [55, 56]. Even, ultrasound-guided PRP (by using 
peppering technique and ~2 ml/2 times/2 weeks intervals) was found to be superior 
from ESWT in the treatment of patellar tendinopathy [57].
While PRP treatment was shown to be significant in patellar and Achilles 
tendinopathy case series, it was similar as saline injection in RCTs. However, it 
is indicated that saline injection cannot be considered as placebo because of the 
mechanical effect caused by the needle and bleeding [58].
PRP injections were considered successful in the treatment of chronic refractory 
Achilles tendinitis [59–61].
2.2.2.4 Osteoarthritis
Intra-articular PRP and hyaluronic acid provide similar clinical improvement. 
The success rate was higher in the joints with low degeneration at 6 and 12 month 
Figure 1. 
Intra-articular PRP applications to the knee joint.
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follow-up of PRP [62]. PRP is superior to placebo in the treatment of early stage 
knee osteoarthritis. Interestingly, a similar improvement is observed between single 
and two doses of PRP [63] (Figure 1).
Indications and contraindications of PrT and PRP applications are shown in Table 1.
3. Conclusion
It is obvious that increasing of the regenerative injection treatment types will 
continue progressively in the future. At the present time, PrT can be used as a 
simple, reliable, fast-acting treatment method in patients resistant to conservative 
treatment. Although PRP is used for the same diseases as PrT, it can also be used in 
acute cases unlike PrT. Both methods can be used with confidence in pain manage-
ment. Proper patient selection is the most important issue to obtain effective results 
from methods.
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Application Indications Contraindications
PrT Chronic musculoskeletal 
disorders;




Hereditary or acquired bleeding tendency,
Osteomyelitis,
Systemic infection,
Chronic infection history or active infection in the 
treatment region, Rheumatic or other systemic 
inflammatory disease,
Oncological diseases,
Having been injected local corticosteroid within 
12 weeks, Allergy to the solution that is using for PrT.
PRP Acute/chronic musculoskeletal, 
cartilage and bone diseases;
Chronic tendinopathies and 
enthesitis,
Acute/chronic ligament injuries,





Delayed fracture healing, 
Nonunions,
Intervertebral disc injuries




Bowel thrombin allergy (if it is used as an activator)
Table 1. 
Indications and contraindications of PrT and PRP applications.
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